ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
PHAXIAM Therapeutics SA

PHAXIAM Therapeutics SA (PHXM)

1.782
-0.006
(-0.34%)
마감 25 1월 1:30AM

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

가격
1.782
매수가
1.75
매도가
1.79
거래량
1,930
1.75 일간 변동폭 1.79
1.50 52주 범위 4.18
market_cap
전일 종가
1.788
개장가
1.79
최근 거래 시간
22
@
1.782
마지막 거래 시간
재정 규모
-
VWAP
-
평균 볼륨(3m)
15,413
발행 주식
30,989,584
배당수익률
-
주가수익률
-2.35
주당순이익(EPS)
-0.76
매출
1.33M
순이익
-23.49M

PHAXIAM Therapeutics SA 정보

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
본부
Lyon, Rhone, Fra
설립됨
-
PHAXIAM Therapeutics SA is listed in the Pharmaceutical Preparations sector of the 유로넥스트 (Euronext) with ticker PHXM. The last closing price for PHAXIAM Therapeutics was 1.79 €. Over the last year, PHAXIAM Therapeutics shares have traded in a share price range of 1.50 € to 4.18 €.

PHAXIAM Therapeutics currently has 30,989,584 shares in issue. The market capitalisation of PHAXIAM Therapeutics is 55.41 € million. PHAXIAM Therapeutics has a price to earnings ratio (PE ratio) of -2.35.

PHXM 최신 뉴스

PHAXIAM Therapeutics annonce son calendrier financier 2025

Regulatory News: PHAXIAM Therapeutics (Euronext : PHXM – FR0011471135), société biopharmaceutique qui développe des traitements innovants pour les infections bactériennes sévères et résistantes...

PHAXIAM Therapeutics annonce des données cliniques actualisées issues de patients traités sous statut compassionnel en Europe

Des résultats cliniques prometteurs observés chez les 88 premiers patients évalués, confirmant l'innocuité et un bénéfice clinique important pour les patients Contrôle de l'infection à 3 mois...

PHAXIAM : Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 décembre 2024

Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Regulatory News: PHAXIAM (Paris:PHXM) : Place de cotation : Euronext Paris (Compartiment C - Code ISIN : FR001400K4B1 –...

PHAXIAM Therapeutics présente les données cliniques de l’étude pilote PhagoDAIR, dont les résultats confirment le design de l’étude clinique de Phase II GLORIA

Cette étude pilote non comparative1 incluant des patients présentant une infection sur prothèse ostéo-articulaire (PJI), a recruté 29 patients, dont 26 évaluables pour l’activité clinique sur...

PHAXIAM Therapeutics : information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 novembre 2024

PHAXIAM Therapeutics : information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 novembre 2024 Article 223-16 du Règlement Général de...

PHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024

PHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024 Article 223-16 of general regulation of French...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.018-11.81.821.7352981.78171463DE
40.0925.443786982251.691.851.6281731.73857053DE
120.17811.09725685791.6042.1451.5154131.74715783DE
26-0.198-101.982.1451.5102061.751478DE
52-2.398-57.36842105264.184.181.589202.136828DE
1560.992125.5696202530.7960.353248801.19964479DE
2600.992125.5696202530.7960.353248801.19964479DE

PHXM - Frequently Asked Questions (FAQ)

What is the current PHAXIAM Therapeutics share price?
The current share price of PHAXIAM Therapeutics is 1.782 €
How many PHAXIAM Therapeutics shares are in issue?
PHAXIAM Therapeutics has 30,989,584 shares in issue
What is the market cap of PHAXIAM Therapeutics?
The market capitalisation of PHAXIAM Therapeutics is EUR 55.41M
What is the 1 year trading range for PHAXIAM Therapeutics share price?
PHAXIAM Therapeutics has traded in the range of 1.50 € to 4.18 € during the past year
What is the PE ratio of PHAXIAM Therapeutics?
The price to earnings ratio of PHAXIAM Therapeutics is -2.35
What is the cash to sales ratio of PHAXIAM Therapeutics?
The cash to sales ratio of PHAXIAM Therapeutics is 41.59
What is the reporting currency for PHAXIAM Therapeutics?
PHAXIAM Therapeutics reports financial results in EUR
What is the latest annual turnover for PHAXIAM Therapeutics?
The latest annual turnover of PHAXIAM Therapeutics is EUR 1.33M
What is the latest annual profit for PHAXIAM Therapeutics?
The latest annual profit of PHAXIAM Therapeutics is EUR -23.49M
What is the registered address of PHAXIAM Therapeutics?
The registered address for PHAXIAM Therapeutics is 60 AVENUE ROCKEFELLER, LYON, RHONE, 69008
What is the PHAXIAM Therapeutics website address?
The website address for PHAXIAM Therapeutics is www.phaxiam.com
Which industry sector does PHAXIAM Therapeutics operate in?
PHAXIAM Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
MLCOTCoretech 5
0.021 €
(61.54%)
102.18k
AELISAelis Farma SA
3.36 €
(46.09%)
24.42k
ALIMOGroupimo
0.182 €
(43.31%)
484
ALCWECharwood Energy SA
3.14 €
(36.52%)
10.6k
FPGUnion Tech Info
0.268 €
(26.42%)
11.65k
DMSBSDiagnostic Medical Systems
0.0045 €
(-35.71%)
818
ALTROTronic s Microsystems
3.90 €
(-28.44%)
23
ALNMRNamR SA
0.344 €
(-28.33%)
90.71k
GNROGeNeuro SA
0.1625 €
(-27.46%)
1.06M
ALOKWGroupe Okwind SA
3.30 €
(-20.29%)
35.38k
ATOAtos SE
0.0021 €
(0.00%)
1.18B
BCPBanco Comercial Portugues SA
0.5154 €
(-0.62%)
61.83M
ALCYBCybergun
0.0001 €
(0.00%)
56.47M
ALVERVergnet
0.0014 €
(0.00%)
19.39M
EDPEDP SA
2.901 €
(-0.65%)
13.72M
tombe tombe 4 분 전
Do you think he already knows expected DEA quotas for the next year? It would be tough to predict growth if he does not. Then he could predict numbers that are not reached and be called a liar (lol). But the stick price would sink at that time instead of this reporting quarter Sounds like a
ELTP
Rainer Rainer 5 분 전
nice action on TKMO RITE
TKMO
BlazingStocks BlazingStocks 5 분 전
$BURU News October 08, 2024
CORRECTION – Liqueous LP Announces $65 Million Financing Program in Nuburu Inc. (BURU), Highlighting Comprehensive Financing with Limited Dilution
https://finance.yahoo.com/news/correction-liqueous-lp-announces-65-021800476.html
BURU
Catpole Catpole 5 분 전
Just imagine what a 2 million hell Mary buy set at .0024 would do. Could get interesting real quick.
APRU
BottomBounce BottomBounce 5 분 전
$NIO Golden CROSS
NIO
Filterthenoise Filterthenoise 5 분 전
Ticky tok frauds 🎅
RNVA
martyDg martyDg 5 분 전



Okay. I'm a fake investor. lol. Dream on.
NWBO
BPETER BPETER 5 분 전
I see no motivation to buy.
CLHI
glenn1919 glenn1919 5 분 전
MULN.................................https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=3&dy=0&id=p11960084343
MULN
bigworld bigworld 5 분 전
gfp: I'll probably be out of UVXY by March 1st if we haven't had a rug pull before then. I just think the market is in a precarious situation. Valuations are close to record highs. The bond market needed Fed intervention to keep from rising over 4.8% on the 10 Year. Market breadth is dreadful. 75%
UVXY
MahinAgency MahinAgency 5 분 전
OTCMKTS: $CBDL big update Stay Tuned👍👍

Lowering the authorized shares by 35%  and initiating the share buyback.   Expect more LOIs in the near future with high revenue producing dispensaries!

CBDL
kittycattttt kittycattttt 6 분 전
NEWS: over $200,000,000 in gold have been found thanks to NBRI

NEWS LIKE THAT WOULD BE GREAT...
NBRI
Monksdream Monksdream 6 분 전
TWLO, new 52 high
https://investorshub.advfn.com/uimage/uploads/2025/1/24/[lucvIMG_4790.gif
TWLO
Filterthenoise Filterthenoise 6 분 전
FOXO got em worrying bout every EM tik🎅
FOXO
pos_stock_hoarder pos_stock_hoarder 6 분 전
Would have loved the live video too!
 stock king 1 stock king 1 6 분 전
Too Funny , yeppers Gcan a fing scam and this crooked CEO screwed a lot of good people now he wants help pumping it . To funny
GCAN
Pacha78 Pacha78 6 분 전
DK buying?
Lol
MCIC
MahinAgency MahinAgency 6 분 전
Accredited Solutions, Inc. (OTC: ASII) GlobeTopper Achieves $39.5M in 2024 Revenue, $4.3M in December
ASII
CommodityCoverage CommodityCoverage 7 분 전
Thiogenesis Therapeutics (TTI.v) is a groundbreaking clinical-stage biotech company revolutionizing the treatment of rare mitochondrial dysfunction diseases through its innovative thiol-active compounds: https://x.com/StckMasterFlash/status/1882535523035791823

Its flagship product, T
TTI
Helloman1 Helloman1 7 분 전
All these buys but not moving?
GRLF
georgie18 georgie18 7 분 전
Sure is...🥳...
NVNI
RIGATONI RIGATONI 8 분 전
$8.80 halted ~Rig
RickNagra RickNagra 8 분 전
That makes more sense.  In some countries they use a period instead of a comma.
FNMA
shadolane shadolane 8 분 전
And .717 this month based on actual distribution into my account.

Quite a slide from the last one.
TSLY
BDEZ BDEZ 8 분 전
Sweet…

최근 히스토리

Delayed Upgrade Clock